Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of the firm’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $27.67, for a total value of $138,350.00. Following the sale, the director now directly owns 37,467 shares of the company’s stock, valued at approximately $1,036,711.89. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of NASDAQ LNTH traded up $0.29 during mid-day trading on Friday, reaching $28.26. The company had a trading volume of 270,313 shares, compared to its average volume of 348,528. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.82 and a current ratio of 4.57. Lantheus Holdings Inc has a one year low of $12.59 and a one year high of $29.80. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of 30.06, a price-to-earnings-growth ratio of 2.12 and a beta of 1.49. The company has a 50-day moving average price of $27.01.
Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 EPS for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.03. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. The company had revenue of $86.51 million for the quarter, compared to analysts’ expectations of $86.80 million. Equities research analysts predict that Lantheus Holdings Inc will post 1.11 EPS for the current fiscal year.
Several research firms have weighed in on LNTH. BidaskClub cut Xencor from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 11th. Zacks Investment Research cut GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 24th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $23.33.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.